Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Several Brand-Name Drug Makers Intend to Withdraw “G1” LLPs
July 4, 2018
- LDP Lawmakers Launch New Study Group on Life Science Industry
July 3, 2018
- MHLW OKs 1st Pfizer Biosimilar, Add’l Indications and Dosages
July 3, 2018
- MHLW Approves Entyvio, Imfinzi, Lynparza Breast Cancer Use, and More
July 3, 2018
- PMDA Reveals First 2 Cases of MID-NET Regulatory Use
July 2, 2018
- LDP’s Patch Panel Boots Up with Bigwig Noda as Chairman
June 28, 2018
- MHLW to Remove Pregnancy Contraindication for 3 Immunosuppressants
June 27, 2018
- Ryukaikon Working Group to Discuss Rebates Offered to Make Up for Higher Invoice Prices
June 26, 2018
- New LDP Study Group to Kick Off with Focus on Innovation in Life Science
June 25, 2018
- PMDA Wants to Increase Safety Staffers to 270 by FY2023: Official
June 21, 2018
- Public Insurance Should Cover Pricy Drugs, Rather than Cold Medicines: MHLW’s Top MD Bureaucrat
June 21, 2018
- PMDA Slips to Second in Time-to-Approval Ranking
June 21, 2018
- LDP’s Pharma Study Group to Form Panel for Patch Medications, Proposal Due Out This Autumn
June 20, 2018
- PMDA Reveals Zero Company Request So Far for MID-NET Database Use, but Says Several Interested
June 19, 2018
- Japan Cabinet Adopts 2018 Honebuto Policy, Inscribes Possible HTA Use in New Drug Listing
June 18, 2018
- Authorized Generics for Aimix, Cravit IV Join NHI Price List
June 15, 2018
- Chuikyo Agrees on No Willing-to-Pay Cost Survey before CEA Rollout; Experts Say Pilot ICER Thresholds “Justifiable”
June 14, 2018
- Keytruda/Ibrance Added to Pilot CEA Drug List, but There Won’t Be Price Tweaks
June 14, 2018
- Japan’s 1st Conditional OK Might Come This Autumn for Pfizer’s Next-Gen ALK Inhibitor Lorlatinib
June 13, 2018
- LDP’s Eto Study Group Submits Proposal to Health Minister
June 13, 2018
ページ
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…